Active Cell & Gene Therapy Leukemia Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

How It Works

1. Share a Few Details — Enter your cancer type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Cell & Gene Therapy Leukemia Clinical Trials FAQ

What is CAR-T cell therapy and who is eligible for a trial?

CAR-T (chimeric antigen receptor T-cell) therapy involves collecting your T-cells, genetically engineering them to recognize cancer-specific proteins (like CD19, BCMA, or CD22), and infusing them back. FDA-approved products exist for leukemia, lymphoma, and multiple myeloma; clinical trials are testing next-generation constructs and new cancer targets. Eligibility typically requires prior treatment history, adequate organ function, and no active serious infection.

How long does CAR-T cell therapy take from enrollment to treatment?

The manufacturing process (apheresis → cell engineering → quality testing → release) typically takes 3–5 weeks. This is important to consider if your cancer is progressing rapidly. Some trials offer 'bridging therapy' (standard treatment given while your cells are being manufactured) to control the disease. Discuss timing concerns with the trial team early in the process.

What is tumor-infiltrating lymphocyte (TIL) therapy?

TIL therapy harvests immune cells that have already infiltrated your tumor, expands them to large numbers in a lab, and infuses them back. FDA approved lifileucel (Amtagvi) for advanced melanoma in 2024. Clinical trials are testing next-generation TIL products for melanoma, cervical cancer, and other solid tumors. Unlike CAR-T, TIL therapy uses naturally selected cells that already target your specific tumor.

Can I join a cell or gene therapy trial if I've already had a stem cell transplant?

Prior stem cell transplant may be acceptable or even required depending on the trial. For leukemia and lymphoma, some CAR-T trials specifically target patients who have relapsed after transplant. Other trials exclude recent transplant recipients or require a minimum time since transplant. Your current immunosuppression level and graft-versus-host disease status are key eligibility factors — the trial team will evaluate these carefully.

Cell & Gene Therapy Trials by Cancer Type

• Leukemia — Leukemia trials are testing targeted inhibitors, CAR-T therapies, and novel transplant strategies for AML, ALL, CLL, and CML. New treatment options are emerging rapidly across all leukemia types.
• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.
• Multiple Myeloma — Multiple myeloma trials are advancing CAR-T therapies, bispecific antibodies, BCMA-targeted agents, and novel triplet combinations — offering new paths for newly diagnosed and relapsed/refractory patients.
• Melanoma — Melanoma trials are studying next-generation checkpoint inhibitors, tumor-infiltrating lymphocyte (TIL) therapy, and BRAF/MEK targeted combinations — including adjuvant options for resected disease.